More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab
Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.
You may also be interested in...
Biocon reported a decline in profits for the third quarter but recent regulatory wins and advancements for its biosimilars portfolio could potentially bring an uptick in growth going forward.
The latest drug development news and highlights from our US FDA Performance Tracker.
Two Indian firms – Biocon and Dr Reddy’s – have received crucial establishment inspection reports (EIRs) from the US FDA amid improved compliance levels at their manufacturing sites.